Ke Chen1, Guanggai Xia2, Changhua Zhang2, Yunwei Sun1. 1. Department of Gastroenterology, Ruijin Hospital, Shanghai Jiaotong University of Medicine Shanghai 200025, China. 2. Department of Gastrointestinopancreatic Surgery, The First Affiliated Hospital of Sun Yat-Sen University Guangzhou 510089, China.
Abstract
BACKGROUND: Epidemiological studies have shown that smoking increases the risk for colorectal cancer (CRC). Evidence of the guiding significance of smoking history for molecular classification and molecular targeted anti-tumor therapy is not well established. AIMS: To provide indirectly evidence, we conducted a systematic meta-analysis of association between smoking history and different molecular classification. METHODS: We searched in multiple databases up to January 2014, and identified 27 eligible studies. All studies were divided into seven groups based on different molecular alteration categories, which are MSI, CIMP, and three molecular pathway-associated gene alterations (APC, KRAS, P53, BRAF mutation, and APC methylation). Crude odds ratios (ORs) and their 95% confidence intervals (CIs) were calculated to evaluate the association. RESULTS: Smoking showed a significantly positive correlation with P53 mutation (exons 4 to 8), BRAF (codon 600) mutation, MSI positivity, and CIMP positivity, with ORs of 1.25 (95% CI: 1.07-1.45), 1.41 (95% CI: 1.18-1.68), 1.28 (95% CI: 1.12-1.47), and 1.23 (95% CI: 1.01-1.50), respectively. However, smoking was not positively correlated with APC (mutation cluster region) and KRAS (codons 12 and 13) mutation in sporadic CRC patients. CONCLUSIONS: These findings suggested smoking history occurred with P53 mutation, BRAF mutation, MSI positivity, and CIMP positivity in sporadic CRCs; and could guide those specifically therapeutic designs when molecular classification with genetic test was infeasible. More associated studies should be conducted for strengthening and renewing the current result.
BACKGROUND: Epidemiological studies have shown that smoking increases the risk for colorectal cancer (CRC). Evidence of the guiding significance of smoking history for molecular classification and molecular targeted anti-tumor therapy is not well established. AIMS: To provide indirectly evidence, we conducted a systematic meta-analysis of association between smoking history and different molecular classification. METHODS: We searched in multiple databases up to January 2014, and identified 27 eligible studies. All studies were divided into seven groups based on different molecular alteration categories, which are MSI, CIMP, and three molecular pathway-associated gene alterations (APC, KRAS, P53, BRAF mutation, and APC methylation). Crude odds ratios (ORs) and their 95% confidence intervals (CIs) were calculated to evaluate the association. RESULTS: Smoking showed a significantly positive correlation with P53 mutation (exons 4 to 8), BRAF (codon 600) mutation, MSI positivity, and CIMP positivity, with ORs of 1.25 (95% CI: 1.07-1.45), 1.41 (95% CI: 1.18-1.68), 1.28 (95% CI: 1.12-1.47), and 1.23 (95% CI: 1.01-1.50), respectively. However, smoking was not positively correlated with APC (mutation cluster region) and KRAS (codons 12 and 13) mutation in sporadic CRC patients. CONCLUSIONS: These findings suggested smoking history occurred with P53 mutation, BRAF mutation, MSI positivity, and CIMP positivity in sporadic CRCs; and could guide those specifically therapeutic designs when molecular classification with genetic test was infeasible. More associated studies should be conducted for strengthening and renewing the current result.
Authors: M J Lafuente; X Casterad; M Trias; C Ascaso; R Molina; A Ballesta; S Zheng; J K Wiencke; A Lafuente Journal: Carcinogenesis Date: 2000-10 Impact factor: 4.944
Authors: Wade S Samowitz; Hans Albertsen; Carol Sweeney; Jennifer Herrick; Bette J Caan; Kristin E Anderson; Roger K Wolff; Martha L Slattery Journal: J Natl Cancer Inst Date: 2006-12-06 Impact factor: 13.506
Authors: Douglas K Rex; Dennis J Ahnen; John A Baron; Kenneth P Batts; Carol A Burke; Randall W Burt; John R Goldblum; José G Guillem; Charles J Kahi; Matthew F Kalady; Michael J O'Brien; Robert D Odze; Shuji Ogino; Susan Parry; Dale C Snover; Emina Emilia Torlakovic; Paul E Wise; Joanne Young; James Church Journal: Am J Gastroenterol Date: 2012-06-19 Impact factor: 10.864
Authors: Brenda Diergaarde; Alina Vrieling; Annemieke A van Kraats; Goos N P van Muijen; Frans J Kok; Ellen Kampman Journal: Carcinogenesis Date: 2003-03 Impact factor: 4.944
Authors: Timothy M Barrow; Hagen Klett; Reka Toth; Jürgen Böhm; Biljana Gigic; Nina Habermann; Dominique Scherer; Petra Schrotz-King; Stephanie Skender; Clare Abbenhardt-Martin; Lin Zielske; Martin Schneider; Alexis Ulrich; Peter Schirmacher; Esther Herpel; Hermann Brenner; Hauke Busch; Melanie Boerries; Cornelia M Ulrich; Karin B Michels Journal: J Pathol Date: 2017-09-29 Impact factor: 7.996
Authors: Joseph C Anderson; Audrey H Calderwood; Brock C Christensen; Christina M Robinson; Christopher I Amos; Lynn Butterly Journal: Am J Gastroenterol Date: 2018-11-01 Impact factor: 10.864
Authors: Anastasiya V Snezhkina; George S Krasnov; Anastasiya V Lipatova; Asiya F Sadritdinova; Olga L Kardymon; Maria S Fedorova; Nataliya V Melnikova; Oleg A Stepanov; Andrew R Zaretsky; Andrey D Kaprin; Boris Y Alekseev; Alexey A Dmitriev; Anna V Kudryavtseva Journal: Oxid Med Cell Longev Date: 2016-06-28 Impact factor: 6.543
Authors: Xiaoliang Wang; Efrat Amitay; Tabitha A Harrison; Barbara L Banbury; Sonja I Berndt; Hermann Brenner; Daniel D Buchanan; Peter T Campbell; Yin Cao; Andrew T Chan; Jenny Chang-Claude; Steven J Gallinger; Marios Giannakis; Graham G Giles; Marc J Gunter; John L Hopper; Mark A Jenkins; Yi Lin; Victor Moreno; Reiko Nishihara; Polly A Newcomb; Shuji Ogino; Amanda I Phipps; Lori C Sakoda; Robert E Schoen; Martha L Slattery; Mingyang Song; Wei Sun; Steven N Thibodeau; Amanda E Toland; Bethany Van Guelpen; Michael O Woods; Li Hsu; Michael Hoffmeister; Ulrike Peters Journal: JNCI Cancer Spectr Date: 2021-06-14